-
Innovation Ranking
Innovation Ranking – Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals Inc (Eagle) is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s key commercial products encompass pharmaceutical injectables, including Ryanodex for exertional heatstroke; Bendeka, and Belrapzo, both for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pipeline products of the company include EP-4104 (dantrolene sodium) for exertional heat stroke (EHS) and nerve agent exposure; EA-114 (fulvestrant) for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Non-Small Cell Lung Cancer Drug...
-
Product Insights
Hepatitis C – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis C - Drugs In Development, 2023’, provides an overview of the Hepatitis C pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Post Operative Nausea And Vomiting – Drugs In Development, 2023
Global Markets Direct’s, ‘Post Operative Nausea And Vomiting - Drugs In Development, 2023’, provides an overview of the Post Operative Nausea And Vomiting pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post Operative Nausea And Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Community-Acquired Bacterial Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Community-Acquired Bacterial Pneumonia - Drugs In Development, 2023’, provides an overview of the Community-Acquired Bacterial Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community-Acquired Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Drugs In Development, 2023
Global Markets Direct’s, ‘End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2023’, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Hormone Sensitive Breast Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Hormone Sensitive Breast Cancer - Drugs In Development, 2023’, provides an overview of the Hormone Sensitive Breast Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hormone Sensitive Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...